Abstracts tagged "Biologics and abatacept"

Abstract Number: 1431 • 2013 ACR/ARHP Annual Meeting
Algorithms Using Genome-Wide SNP Analysis For Prediction Of Efficacy and Adverse Events Of Abatacept Using Two Population Samples From Multiple Medical Cohorts
Tsukasa Matsubara¹, Satoru Koyano², Keiko Funahashi², Takako Miura¹, Kosuke Okuda¹, Takeshi Nakamura¹, Mitsuyoshi Iwahashi³, Tomomi Tsuru⁴, Shoichi Uchimura⁵, Shigeru Honjo⁶, Akira Sagawa⁷, Takeo Sakurai⁸, Hiroaki Matsuno⁹, Tomomaro Izumihara¹⁰, Eisuke Shono¹¹, Kou Katayama¹², Toyomitsu Tsuchida¹³ and Motohiro Oribe¹⁴, ¹Matsubara Mayflower Hospital, Kato, Japan, ²Research Institute of Joint Diseases, Kobe, Japan, ³Higashi-Hiroshima Memorial Hospital, Higashi-hiroshima, Japan, ⁴PS Clinic, Fukuoka, Japan, ⁵Kanzaki Municipal General Hospital, Kanzaki, Japan, ⁶Honjo Rheumatism Clinic, Takaoka, Japan, ⁷Sagawa Akira Rheumatology Clinic, Sapporo, Japan, ⁸Inoue Hospital, Takasaki, Japan, ⁹Matsuno Clinic for Rheumatic Diseases, Toyama, Japan, ¹⁰Izumihara Rheumatic and Medical Clinic, Kagoshima, Japan, ¹¹Shono Rheumatology Clinic, Fukuoka, Japan, ¹²Katayama Orthopedic Rheumatology Clinic, Asahikawa, Japan, ¹³Tsuchida Clinic, Chiba, Japan, ¹⁴Oribe Rheumatism and Internal Medicine Clinic, Oita, Japan
Background/Purpose: Abatacept (ABT), a CTLA4-Ig fusion protein agent targeted to T-cells, is a relatively new biological agent for RA treatment in Japan. However, there is…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].